An unexplained death at a Russian plague research institute has prompted international scrutiny. The incident raises questions about laboratory safety, transparent reporting, and infection prevention preparedness while the cause remains unconfirmed.
|Articles|November 21, 2005
FDA Advisory Committee Affirms Safety of Tamiflu in Children
Advertisement
NUTLEY, N.J. -- The Pediatric Advisory Committee of the Food and Drug Administration (FDA) has confirmed the safety of Tamiflu (oseltamivir phosphate) in children following a scheduled comprehensive review of data about the use of Tamiflu in children. According to Dr. Robert M. Nelson, chairman of the committee, there is "no concern at all" that Tamiflu played a role in the reported deaths of children with influenza in Japan. Nelson is an associate professor in the department of anesthesia and critical care at The Children's Hospital of Philadelphia.
The FDA indicated that it intends to continue normal monitoring of the safety of Tamiflu for use in children, but found no basis for changing the labeling of the product for neuropsychiatric issues. Roche intends to work with the FDA to change the drug's labeling based on adverse skin events that have occurred in a small number of patients, mostly in Japan. The FDA said it would report back to the committee in two years.
"We welcome the outcome of the FDA advisory committee and look forward to working with the FDA and other health authorities to extend our knowledge of the use of Tamiflu and its safety profile. The positive role of Tamiflu remains unchanged," commented William M. Burns, CEO Roche Pharma Division.
The meeting of the Pediatric Advisory Committee on Nov. 18, 2005 was a scheduled one at which adverse events for eight medicines used in children were reviewed. Tamiflu was among the drugs reviewed because it was granted pediatric exclusivity in March 2004. Pediatric exclusivity is granted as an incentive to industry to study the use of medicines in children.
Source: Roche
Advertisement
Related to this article
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.
This week's coverage in Infection Control Today centered on a common thread: the systems, partnerships, and data that let infection prevention teams catch problems before patients are harmed.
UPMC’s genomic surveillance initiative earned national recognition for patient safety. Alexander Sundermann, DrPH, CIC, FAPIC, AL-CIP, explains how the award could help infection preventionists secure leadership support and sustainable funding for earlier outbreak detection.
Knowing the protocol is only the beginning. In The Clean Bite, Sherrie Busby explores how explaining the why, addressing staff concerns, and creating clear procedures can help dental teams make infection control part of everyday practice.
What might infection prevention rounds miss when visible conditions dominate the conversation? Tommy Davis, PhD, CMIP, a member of ICT's executive advisory board, makes the case for structured observations of clinical workflows, shared accountability, and greater attention to environmental services staff’s insights.
A proposed $27.7 million reduction in AHRQ funding raises questions about support for infection prevention research and implementation. Here is what the September 25 announcement identifies, as well as what remains unknown about specific IPC programs.
Advertisement
Advertisement